Updates and Best Practices for the Management of Primary Biliary Cholangitis: Pharmacist and Nurse Perspectives (a Filmed Panel Discussion)
Released On
August 26, 2025
Expires On
February 26, 2026
Media Type
Internet
Estimated Time to Complete Activity
90 minutes
Specialty
Gastroenterology
Topics
Biliary Cholangitis
Providers/Grant Support
Jointly provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).
This activity is supported by an independent educational grant from Ipsen Biopharmaceuticals, Inc.
Credit Available
- Nurses - 1.5 Contact Hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses
- Pharmacists - 1.5 Contact Hours (provided by Postgraduate Healthcare Education (PowerPak) [PHARMACISTS: PLEASE GO TO POWERPAK at https://www.powerpak.com/course/preamble/126782 TO COMPLETE THIS LESSON AND CLAIM CREDIT.]
Target Audience
This activity is designed to meet the educational needs of Pharmacists, Nurses and Advanced Practice Registered Nurses.
Program Overview
This activity will equip pharmacists and nurses with comprehensive knowledge and understanding of primary biliary cholangitis (PBC), including the prevalence, pathophysiology, burden of disease, and how the standards of care may change with new emerging treatment options to ensure optimal patient care and quality of life.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the prevalence, pathophysiology, and disease burden of primary biliary cholangitis (PBC)
- Summarize the efficacy and safety data for novel and emerging treatment options for PBC
- Develop effective approaches for improving PBC treatment goals through patient-centered care and shared decision-making
Faculty
Shubha Bhat, PharmD, MS
Clinical Pharmacist, Gastroenterology
Pharmacy & Digestive Disease Institute
Cleveland Clinic
Cleveland, OH
Dr. Shubha Bhat is a dedicated clinical pharmacy specialist with a focus on gastroenterology. In her practice, she plays a vital role in optimizing patients' medication experience, overseeing education, safety monitoring, and the management of adverse effects for individuals with gastrointestinal conditions. Beyond patient care, Dr. Bhat actively contributes to research and teaching, shaping the next generation of clinical pharmacists. She earned her Doctor of Pharmacy degree from Northeastern University in Boston, Massachusetts, followed by a Master’s degree in Clinical Sciences from the University of Colorado. Dr. Bhat's extensive postgraduate training includes a PGY1 Pharmacy Residency at Boston Medical Center, a PGY2 Ambulatory Care Residency at UIC, and an Ambulatory Care Outcomes Fellowship at the University of Colorado.
Holly Chitwood, DNP, APRN, FNP-C, AGACNP-BC
Assistant Professor
Acute Care Pediatric Nurse Practitioner Co-Track Coordinator
Markey Cancer Center, Division of Medical Oncology
University of Kentucky College of Nursing
Lexington, KY
Dr. Holly Chitwood earned a bachelor's of science in social work from the University of the Cumberlands in 2001. Dr. Chitwood began her nursing career in 2006 and has since completed an MSN with a Family Nurse Practitioner degree at Lincoln Memorial University, a post master's Adult Gerontology Acute Care Nurse Practitioner certificate, a doctorate of nursing practice, and a post master’s Pediatric Acute Care Nurse Practitioner certificate from the University of Kentucky. Dr. Chitwood is a triple board-certified family primary care, adult-gerontology acute care, and pediatric acute care nurse practitioner. She currently practices as an APRN at the University of Kentucky Chandler Medical Center with a focus on gastrointestinal, hepatobiliary, and sarcoma cancers. In addition, Dr. Chitwood is an Assistant Professor in the Doctoral Nurse Practitioner Program at the University of Kentucky.
Accreditation Statements
PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-9999-25-044-H01-P
Credits: 1.5 hour (0.15 ceu)
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosures of Conflicts of Interest
Dr. Bhat has disclosed that she has served as a consultant/advisory board member for Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, and Janssen.
Dr. Chitwood has disclosed that she serves as a paid consultant for the Oncology Nursing Society, the Journal of Advance Practice Providers in Oncology, and Barkley and Associates (as a pediatric certification question reviewer.)
The clinical reviewer, Kimmy Nguyen, PharmD has no actual or potential conflicts of interest in relation to this program.
Susanne Batesko, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
The PIM planners and others have nothing to disclose.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
Instructions for Participation and Credit
Pharmacists, please go to https://www.powerpak.com/course/preamble/126782 to complete this lesson and claim credit.
Nurses, there are no fees for participating and receiving CE credit for this enduring activity. To receive CE credit participants must:
- Read the CE information and faculty disclosures.
- Participate in the online activity.
- Complete the Posttest.
- Submit the evaluation form.
Certificates will be immediately available for the participant.
Disclosure of Unlabeled Use
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Ipsen Biopharmaceuticals, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.
Contact Information
For CME questions please contact: [email protected]